Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock

被引:62
|
作者
Hohn, Andreas [1 ]
Schroeder, Stefan [2 ]
Gehrt, Anna [3 ]
Bernhardt, Kathrin [3 ]
Bein, Berthold [4 ]
Wegscheider, Karl [5 ]
Hochreiter, Marcel [6 ]
机构
[1] Ruhr Univ Bochum, BG Univ Hosp Bergmannsheil, Dept Anaesthesiol Intens Care Palliat Care & Pain, D-44789 Bochum, Germany
[2] Hosp Duren Gem GmbH, Dept Anaesthesiol Intens Care Med & Pain Therapy, D-52351 Duren, Germany
[3] West Coast Hosp, Dept Anesthesiol & Intens Care Med, D-25746 Heide, Germany
[4] Univ Hosp Schleswig Holstein, Dept Anesthesiol & Intens Care Med, D-24105 Kiel, Germany
[5] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, D-20246 Hamburg, Germany
[6] Univ Heidelberg Hosp, Dept Anesthesiol, D-69120 Heidelberg, Germany
关键词
Procalcitonin; Sepsis; Economical outcomes; Intensive care; RESPIRATORY-TRACT INFECTIONS; VENTILATOR-ASSOCIATED PNEUMONIA; INTENSIVE-CARE PATIENTS; ANTIMICROBIAL RESISTANCE; DISEASES-SOCIETY; CONTROLLED-TRIAL; DURATION; GUIDELINES; EPIDEMIOLOGY; INITIATION;
D O I
10.1186/1471-2334-13-158
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Procalcitonin (PCT)-protocols to guide antibiotic treatment in severe infections are known to be effective. But less is known about the long-term effects of such protocols on antibiotic consumption under real life conditions. This retrospective study analyses the effects on antibiotic use in patients with severe sepsis and septic shock after implementation of a PCT-protocol. Methods: We conducted a retrospective ICU-database search for adult patients between 2005 and 2009 with sepsis and organ dysfunction who where treated accordingly to a PCT-guided algorithm as follows: Daily measurements of PCT (BRAHMS PCT LIA (R); BRAHMS Aktiengesellschaft, Hennigsdorf, Germany). Antibiotic therapy was discontinued if 1) clinical signs and symptoms of infection improved and PCT decreased to <= 1 ng/ml, or 2) if the PCT value was >1 ng/ml, but had dropped to 25-35% of the initial value within three days. The primary outcome parameters were: antibiotic days on ICU, ICU re-infection rate, 28-day mortality rate, length of stay (LOS) in ICU, mean antibiotic costs (per patient) and ventilation hours. Data from 141 patients were included in our study. Primary outcome parameters were analysed using covariance analyses (ANCOVA) to control for effects by gender, age, SAPS II, APACHE II and effective cost weight. Results: From baseline data of 2005, duration of antibiotic therapy was reduced by an average of 1.0 day per year from 14.3 +/- 1.2 to 9.0 +/- 1.7 days in 2009 (p=0.02). ICU re-infection rate was decreased by yearly 35.1% (95% CI -53 to -8.5; p=0.014) just as ventilation hours by 42 hours per year (95% CI -72.6 to -11.4; p=0.008). ICU-LOS was reduced by 2.7 days per year (p<0.001). Trends towards an average yearly reduction of 28-day mortality by -22.4% (95% CI -44.3 to 8.1; p=0.133) and mean cost for antibiotic therapy/patient by -14.3 Euro (95% CI -55.7 to 27.1) did not reach statistical significance. Conclusions: In a real-life clinical setting, implementation of a PCT-protocol was associated with a reduced duration of antibiotic therapy in septic ICU patients without compromising clinical or economical outcomes.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: A systematic review and meta-analysis of randomized controlled trials
    Kopterides, Petros
    Siempos, Ilias I.
    Tsangaris, Iraklis
    Tsantes, Argirios
    Armaganidis, Apostolos
    CRITICAL CARE MEDICINE, 2010, 38 (11) : 2229 - 2241
  • [22] Ineffectiveness of procalcitonin-guided antibiotic therapy in severely critically ill patients: A meta-analysis
    Peng, Fei
    Chang, Wei
    Xie, Jian-Feng
    Sun, Qin
    Qiu, Hai-Bo
    Yang, Yi
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2019, 85 : 158 - 166
  • [23] Empiric Antibiotic Therapy for Severe Sepsis and Septic Shock
    Oshima, Taku
    Kodama, Yoshiyuki
    Takahashi, Waka
    Hayashi, Yosuke
    Iwase, Shinya
    Kurita, Takeo
    Saito, Daiki
    Yamaji, Yoshihiro
    Oda, Shigeto
    SURGICAL INFECTIONS, 2016, 17 (02) : 210 - 216
  • [24] Procalcitonin-Guided Antibiotic Therapy Duration in Critically Ill Adults
    Walker, Caroline
    AACN ADVANCED CRITICAL CARE, 2015, 26 (02) : 99 - 106
  • [25] Procalcitonin-guided antibiotic therapy in critically ill adults: a meta-analysis
    Zhang, Tao
    Wang, Yan
    Yang, Qianting
    Dong, Yalin
    BMC INFECTIOUS DISEASES, 2017, 17
  • [26] Procalcitonin-guided antibiotic therapy in AECOPD patients: Overview of systematic reviews
    Di, Jiaqi
    Li, Xuanlin
    Xie, Yang
    Yang, Shuguang
    Yu, Xueqing
    CLINICAL RESPIRATORY JOURNAL, 2021, 15 (06): : 579 - 594
  • [27] Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial
    Soares Lima, Stella Sala
    Nobre, Vandack
    de Castro Romanelli, Roberta Maia
    Clemente, Wanessa Trindade
    da Silva Bittencourt, Henrique Neves
    Mourao Melo, Ana Catarina
    Botelho Salomao, Luciana Caetano
    Serufo, Jose Carlos
    ANNALS OF HEMATOLOGY, 2016, 95 (07) : 1169 - 1176
  • [28] Impact of the timeliness of antibiotic therapy on the outcome of patients with sepsis and septic shock
    Asner, Sandra A.
    Desgranges, Florian
    Schrijver, Irene T.
    Calandra, Thierry
    JOURNAL OF INFECTION, 2021, 82 (05) : 125 - 134
  • [29] Procalcitonin-guided antibiotic therapy in intensive care unit patients: a systematic review and meta-analysis
    Huang, Hui-Bin
    Peng, Jin-Min
    Weng, Li
    Wang, Chun-Yao
    Jiang, Wei
    Du, Bin
    ANNALS OF INTENSIVE CARE, 2017, 7
  • [30] Procalcitonin-Guided Treatment on Duration of Antibiotic Therapy and Cost in Septic Patients (PRODA): a Multi-Center Randomized Controlled Trial
    Jeon, Kyeongman
    Suh, Jae Kyung
    Jang, Eun Jin
    Cho, Songhee
    Ryu, Ho Geol
    Na, Sungwon
    Hong, Sang-Bum
    Lee, Hyun Joo
    Kim, Jae Yeol
    Lee, Sang-Min
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2019, 34 (14)